Table 2.
COUNTRY | Responses (n) | Institutions (n) | Insurance coverage | Pharmacogenetic tests listed in the survey | Additional tests | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CYP2C19 | CYP2C9 | CYP2D6 |
CYP3A4
CYP3A5 |
DPYD | HLA‐A*31:01 B*15:02 | SLCO1B1 | TPMT | UGT1A1 | |||||
Low HDI | |||||||||||||
Eritrea | 1 | 1 | N/A | x | x | x | x | x | x | x | x | x | |
Nigeria | 1 | 1 | N/A | x | x | x | x | x | x | x | x | x | |
Sudan | 1 | 1 | ? | ? | ? | √ | √ | ? | ? | ? | ? | ? | |
Medium HDI | |||||||||||||
Bangladesh | 2 | 2 | N/A | x | x | x | x | x | x | x | x | x | |
India | 13 | 13 | It depends | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
Indonesia | 3 | 3 | N/A | x | x | x | x | x | x | x | x | x | |
Pakistan | 1 | 1 | N/A | x | x | x | x | x | x | x | x | x | |
High HDI | |||||||||||||
Brazil | 6 | 5 | It depends | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
Iran | 2 | 2 | ? | ? | ? | ? | ? | ? | ? | ? | √ | ? | |
Jordan | 5 | 3 | ? | x | x | x | x | x | x | x | √ | x | |
Lebanon | 2 | 2 | ? | √ | √ | √ | x | x | x | x | √ | x | |
Mexico | 2 | 2 | ? | x | √ | √ | √ | ? | √ | ? | ? | ? | |
Republic of Moldova | 1 | 1 | N/A | x | x | x | x | x | x | x | x | x | |
Turkey | 1 | 1 | ? | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
Very high HDI—other | |||||||||||||
Argentina | 1 | 1 | x | √ | √ | √ | √ | x | x | x | x | x | CYP2A6, CYP2B6, NAT2, ABCB1, OCT |
Australia | 2 | 2 | x | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
Brunei | 1 | 1 | N/A | x | x | x | x | x | x | x | x | x | |
Malaysia | 2 | 2 | x | √ | √ | √ | √ | √ | √ | x | √ | √ | |
Saudi Arabia | 1 | 1 | ? | x | x | x | x | x | ? | x | ? | ? | |
Singapore | 1 | 1 | x | √ | ? | ? | ? | √ | √ | √ | ? | √ | HLA‐B*5701, HLA‐B*5801 |
United Arab Emirates | 1 | 1 | ? | ? | x | x | ? | ? | ? | x | √ | ? | |
Very high HDI—Europe | |||||||||||||
Belarus | 1 | 1 | x | √ | √ | √ | √ | ? | √ | √ | ? | √ | ABC |
Croatia | 1 | 1 | √ | √ | √ | √ | √ | √ | x | √ | √ | √ | ABCB1, ABCG2, NAT2 |
Denmark | 1 | 1 | x | √ | √ | √ | √ | x | x | ? | ? | ? | |
Estonia | 1 | 1 | ? | √ | √ | √ | √ | ? | ? | ? | √ | ? | |
France | 1 | 1 | ? | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
Germany | 3 | 3 | x | √ | √ | √ | √ | √ | √ | √ | √ | √ | ABCB1, ABCG2 |
Iceland | 1 | 1 | N/A | x | x | x | x | x | x | x | x | x | |
Italy | 5 | 4 | x | √ | ? | √ | √ | √ | √ | ? | √ | √ | |
Slovenia | 3 | 1 | x | √ | √ | √ | √ | √ | √ | √ | √ | √ | SLC19A1, SLC6A4, MTHFD1, ABCC2 |
Spain | 4 | 4 | It depends | √ | √ | √ | √ | √ | √ | √ | √ | √ | CYP2B6, VKORC1, HLA‐B*5701 |
Sweden | 1 | 1 | x | √ | √ | √ | √ | √ | √ | √ | √ | √ | VKORC1, NAT2, IL28B |
Switzerland | 2 | 2 | It depends | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
The Netherlands | 8 | 5 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | HLA‐B*5701 |
UK | 1 | 1 | ? | ? | √ | ? | ? | ? | ? | ? | ? | ? | VKORC1 |
Very high HDI—North America | |||||||||||||
Canada | 6 | 6 | It depends | √ | √ | √ | √ | √ | √ | √ | √ | √ | VKORC1, IL28B, OPRM1, UGT2B15 |
USA | 59 | 41 | It depends | √ | √ | √ | √ | √ | √ | √ | √ | √ | CYP2B6, CYP4F2, VKORC1, HLA‐B*5701, HLA‐B*5801, G6PD, OPRD1, OPRM1, GRIK1, GRIK4, INFL3, ITPA, NUDT15, RYR1, mt‐RNR1, CACNAIS, CFTR, ADR2A |
HDI: Human Development Index (2018). Number of responses does not total 204 due to missing answers. X = no; √ = yes; ? = uncertain.